News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MDxHealth, Inc. (MXDHF)'s MGMT Test Included in NCCN Guidelines and Awarded Tier 1 Reimbursement Code by American Medical Association


10/16/2013 10:00:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif. and HERSTAL, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company's MGMT (O6-methylguanine-DNA methyl transferase) test, PredictMDx(TM) for Glioblastoma, used to identify patients most likely to respond to targeted therapy, has been included in the 2013 National Comprehensive Cancer Network (NCCN) Guidelines. The NCCN is an alliance of 23 world-leading cancer centers. The new guidelines are published online at www.nccn.org.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES